B2M and B-cell chronic lymphocytic leukemia: Interestingly, increased beta-2-microglobulin (B2M) plasma levels account for two scoring points in the CLL-IPI and are given the same prognostic impact as an unmutated immunoglobulin heavy chain (IGHV) status—a well-established molecular feature associated with biologically more aggressive disease [15,16].